$SLDB Solid announced that it received written communication from the FDA stating the IGNITE DMD Phase 1/2 trial remains on clinical hold and the Company will continue to work with the FDA to address their requests.

#GeneTherapy #DMD $SRPT $PFE

https://t.co/MPahHRzyoX